These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23415672)

  • 1. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
    Braicu EI; Fotopoulou C; Chekerov R; Richter R; Blohmer J; Kümmel S; Stamatian F; Yalcinkaya I; Mentze M; Lichtenegger W; Sehouli J
    Cytokine; 2013 Mar; 61(3):755-8. PubMed ID: 23415672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.
    Braicu EI; Gasimli K; Richter R; Nassir M; Kümmel S; Blohmer JU; Yalcinkaya I; Chekerov R; Ignat I; Ionescu A; Mentze M; Fotopoulou C; Pop C; Lichtenegger W; Sehouli J; ;
    Anticancer Res; 2014 Jan; 34(1):385-91. PubMed ID: 24403492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
    Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
    Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.
    Blohmer JU; Paepke S; Sehouli J; Boehmer D; Kolben M; Würschmidt F; Petry KU; Kimmig R; Elling D; Thomssen C; von Minckwitz G; Möbus V; Hinke A; Kümmel S; Budach V; Lichtenegger W; Schmid P
    J Clin Oncol; 2011 Oct; 29(28):3791-7. PubMed ID: 21860000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.
    Sehouli J; Runnebaum IB; Fotopoulou C; Blohmer U; Belau A; Leber H; Hanker LC; Hartmann W; Richter R; Keyver-Paik MD; Oberhoff C; Heinrich G; du Bois A; Olbrich C; Simon E; Friese K; Kimmig R; Boehmer D; Lichtenegger W; Kuemmel S
    Ann Oncol; 2012 Sep; 23(9):2259-2264. PubMed ID: 22357252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
    Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
    Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance.
    Trejo-Becerril C; Oñate-Ocaña LF; Taja-Chayeb L; Vanoye-Carlo A; Cetina L; Duenas-Gonzalez A
    BMC Cancer; 2005 Jun; 5():65. PubMed ID: 15982417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
    Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
    J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer.
    Kim K; Chie EK; Wu HG; Ha SW; Kim JS; Kim IA; Lee HP
    Gynecol Oncol; 2006 Jun; 101(3):398-402. PubMed ID: 16330087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IIB-IVA).
    Lee YY; Choi CH; Kim CJ; Song TJ; Kim MK; Kim TJ; Lee JW; Kim BG; Lee JH; Bae DS
    Gynecol Oncol; 2010 Mar; 116(3):459-63. PubMed ID: 20004008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
    Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
    Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer.
    Kim HS; Kim JY; Park NH; Kim K; Chung HH; Kim YB; Kim JW; Kim HJ; Song YS; Kang SB
    Gynecol Oncol; 2010 Nov; 119(2):217-24. PubMed ID: 20705335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.
    Hwang YY; Moon H; Cho SH; Kim KT; Moon YJ; Kim SR; Kim DS
    Gynecol Oncol; 2001 Jul; 82(1):88-93. PubMed ID: 11426967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer.
    Angioli R; Plotti F; Montera R; Aloisi A; Luvero D; Capriglione S; Terranova C; De Cicco Nardone C; Muzii L; Benedetti-Panici P
    Gynecol Oncol; 2012 Nov; 127(2):290-6. PubMed ID: 22819938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
    Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C
    Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.
    Havrilesky LJ; Leath CA; Huh W; Calingaert B; Bentley RC; Soper JT; Alvarez Secord A
    Gynecol Oncol; 2004 May; 93(2):429-34. PubMed ID: 15099957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
    Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
    Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical cancer: combined modality therapy.
    Grigsby PW
    Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.